<DOC>
	<DOCNO>NCT01483274</DOCNO>
	<brief_summary>Patients Acute Myelogenous Leukemia ( AML ) relapse allogeneic stem cell transplant cell receive decitabine regulate cancer antigen expression , follow donor lymphocyte infusion autologous dendritic cell ( DC ) . Vaccine Dendritic cell pulse overlap peptide derive MAGE-A1 , MAGE-A3 , NY-ESO-1 .</brief_summary>
	<brief_title>Decitabine Vaccine Therapy Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>For vaccine production , mature DC pulse overlap peptide mix derive full-length NY-ESO-1 , MAGE-A1 , MAGE-A3 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>Inclusion Criteria study enrollment : Signed informed consent discussion alternative therapy . The first six patient be18 65 year old . Patients # 710 range age 2 65 year . Histologically cytogenetically confirm diagnosis acute myelogenous leukemia prior allogeneic SCT , follow risk factor : &gt; second complete response , relapse , time transplant monosomy 5 7 presence high FLT3/ITD allelic ratio patient detectable minimal residual disease ( MRD ) posttransplant &lt; 0.5 % positive recipient leukemia cell flow cytometry Inclusion criterion begin study therapy : Patient least three month posttransplant . Patients must systemic immunosuppression least two week prior start therapy study . ECOG performance status 02 , Lansky performance status &gt; 70 ( see Appendix 1 ) . Hematologic Function : ANC : ≥ 500 ; Platelet count : ≥ 75 . Renal Function : Creatinine clearance radioisotope GFR ≥ 70ml/min/1.73 m2 OR serum creatinine base age/gender use Schwartz formula : Cardiac Function : Patient must normal cardiac function document within two week start treatment cycle 1 : Ejection fraction ( &gt; 55 % ) document echocardiogram fractional shortening ( ≥ 28 % ) document echocardiogram . Liver Function : Total bilirubin ≤ 1.5 x normal age , ALT ( SGPT ) AST ( SGOT ) ≤ 3 x normal age . Room air pulse oximetry &gt; 94 % . Female patient childbearing potential must negative serum pregnancy test within 7 day enrollment . Male female patient must agree use medically acceptable barrier and/or chemical contraceptive method study minimum 3 month last dose chemotherapy study . Subjects must &gt; 3 month &lt; 12 month postSCT time first vaccination . Donor chimerism must &gt; 90 % , assist least two week prior begin treatment Subjects must least 30 day posttransplant enroll study undergo apheresis , must least three month posttransplant begin therapy DAC/vaccine . Stem cell donor source may relate unrelated donor cord blood , relate unrelated donor bone marrow , relate unrelated donor peripheral blood stem cell product . Donors may two HLA ( A , B , C , DR , DQ ) antigen mismatch recipient . Patient history autoimmune disease , specifically inflammatory bowel disease , systemic lupus erythematosis , rheumatoid arthritis . Patient known systemic hypersensitivity DAC , imiquimod , vaccine component . Patient evidence recurrent leukemia . Patient receive systemic corticosteroid immunosuppression . Persistent clinically significant toxicity prior anticancer therapy &gt; Grade 2 ( NCI CTCAE v3.0 ) . Pregnant lactating female exclude . Other active systemic malignancy leukemia expect require therapy within 4 month . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Any condition , opinion investigator , would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result . Patients positive result follow diagnostic test : Hep B Ag , Hep B Core Ab , Hep C Ab , HIV1 Ab , HIV2 Ab , HTLV1 Ab , HTLV2 Ab , RPR . Received investigational new drug within 30 day prior first dose vaccine , schedule receive investigational new course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>vaccine</keyword>
</DOC>